NewLink Genetics Corporation (NewLink) is a biopharmaceutical company focused on discovering, developing and commercializing immunotherapeutic products for cancer treatment. Its portfolio includes both biologic and small-molecule immunotherapy product candidates. The Company's biologic product candidates are based on its HyperAcute immunotherapy technology, which is designed to stimulate the human immune system. NewLink's small-molecule product candidates are focused on breaking the immune system's tolerance to cancer by inhibiting the indoleamine-(2, 3)-dioxygenase pathway. Its lead product candidate algenpantucel-L or HyperAcute Pancreas.

Type
Public
HQ
Ames, US
Founded
1999
Size (employees)
122 (est)
NewLink Genetics was founded in 1999 and is headquartered in Ames, US
Report incorrect company information

NewLink Genetics Office Locations

NewLink Genetics has offices in Ames, Austin and Devens
Ames, US (HQ)
5100 2503 S Loop Dr
Austin, US
100 2700 Vía Fortuna
Devens, US
108 94 Jackson Rd
Show all (3)
Report incorrect company information

NewLink Genetics Financials and Metrics

NewLink Genetics Financials

NewLink Genetics's revenue was reported to be $28.71 m in FY, 2017
USD

Revenue (FY, 2017)

28.7 m

Net income (FY, 2017)

(72 m)

EBIT (FY, 2017)

(72.9 m)

Market capitalization (18-Apr-2018)

142.1 m

Cash (31-Dec-2017)

158.7 m
NewLink Genetics's current market capitalization is $142.1 m.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

1.1 m172.6 m68.5 m35.8 m28.7 m

Revenue growth, %

15691%(60%)(48%)

General and administrative expense

33.2 m31.7 m

R&D expense

93.3 m69.9 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Revenue

39.2 m7.4 m14.2 m5.7 m2 m15.3 m2.8 m10.4 m

General and administrative expense

2.3 m3.3 m2.9 m4.9 m8.4 m7.3 m7.4 m9.2 m9.1 m7.7 m8.2 m8.9 m

R&D expense

6.1 m6.4 m6.5 m10.9 m18 m16.1 m22.5 m21.9 m27.4 m24.5 m15.7 m18.2 m

Operating expense total

8.4 m9.6 m9.3 m15.8 m26.3 m23.4 m29.9 m31.1 m36.5 m32.2 m24 m27.1 m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

61.3 m190.4 m195.6 m131.5 m158.7 m

Accounts Receivable

1.3 m3.7 m5.4 m24.5 m

Inventories

5 m5.9 m

Current Assets

64 m230.5 m208.1 m167.9 m175.5 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Cash

52 m83.7 m76.9 m51.1 m206.6 m203.4 m197.1 m177 m160.5 m148.3 m118.2 m107.8 m

Accounts Receivable

1.2 m251 k161 k2.7 m11 m12.6 m14.5 m6.7 m3.2 m15 m11.3 m

Current Assets

54.1 m85.3 m78.2 m78.8 m251.1 m234.5 m217.2 m189.4 m172 m179.2 m143.2 m130.2 m

PP&E

7.4 m7.2 m6.5 m5.9 m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(31.2 m)102.9 m(40.4 m)(85.2 m)(72 m)

Depreciation and Amortization

891 k1.1 m1.6 m2.1 m1.4 m

Inventories

3.4 m

Accounts Payable

(359 k)7.9 m245 k24.8 m(15.5 m)
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(8.1 m)(9.2 m)(9.2 m)(5.6 m)11.2 m(14.1 m)(15.9 m)(23.7 m)(32.4 m)(15.5 m)(20.9 m)

Accounts Payable

687 k2.9 m4.1 m1.5 m1.5 m3 m1.8 m2.4 m9.6 m
USDY, 2017

Revenue/Employee

235.3 k

Financial Leverage

1.2 x
Show all financial metrics
Report incorrect company information